Login to Your Account

Mateon candidate shows ongoing signs of activity against AML, MDS in early trial

By Michael Fitzhugh
Staff Writer

Monday, July 31, 2017

Mateon Therapeutics Inc. said that, so far, five of 21 people with relapsed/refractory AML or myelodysplastic syndrome have achieved complete remissions after being treated with its vascular disrupting agent, Oxi-4503, in combination with cytarabine.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription